|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||34.83 - 35.24|
|52 Week Range||33.79 - 40.43|
|PE Ratio (TTM)||20.06|
|Forward Dividend & Yield||0.70 (1.95%)|
|1y Target Est||40.57|
Canada possesses more short-term advantages for going public, as cannabis business owners benefit from operating in a market that carries little legal risk. “Sure, nine states have legalized recreational cannabis, but it’s still federally illegal. Canadian company Sunniva, Inc. (CNSX: SNN) plans to obtain licensing in both Canada and California, making it one of the first cannabis companies operating in both regions.
Smith & Nephew's new chief executive confirmed the company's full-year guidance on Thursday after improvement in its U.S. market helped revenues for the artificial hip and knee maker to recover from a tough start to the year. Smith & Nephew (SN.L) said underlying revenue growth for the year was still expected to be 2-3 percent, after it cut its outlook in its previous trading statement in May, one of the last acts of its previous CEO. New boss Namal Nawana said that while Europe remained soft, there had been improvement in the United States, where the company derives about half of its revenues.
LONDON , July 25, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced positive clinical results concerning its JOURNEY™ II Bi-Cruciate Stabilized ...
Under assessment this morning are these four equities: Myomo Inc. (NYSE AMER: MYO), Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), and Insulet Corp. (NASDAQ: PODD). All you have to do is sign up today for this free limited time offer by clicking the link below.
LONDON and NEW YORK , July 3, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence ...
This Monday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), Accuray Inc. (NASDAQ: ARAY), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). All you have to do is sign up today for this free limited time offer by clicking the link below.
The size of Smith & Nephew plc (LSE:SN.), a UK£11.91B large-cap, often attracts investors seeking a reliable investment in the stock market. Big corporations are much sought after by risk-averseRead More...
Smith & Nephew downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker. It also lowered trading profit forecasts, predicting a margin at or above the level achieved last year rather than the 30-70 basis point growth it had targeted. Bohuon, who steps down on Monday, said the business had seen a "mixed performance" in the quarter to end-March, with established markets like the United States and Europe down 2 percent on an underlying basis and emerging markets up 9 percent, resulting in a flat result overall.
Smith & Nephew plc (LSE:SN.) trades with a trailing P/E of 21.7x, which is lower than the industry average of 29.6x. While this makes SN. appear like a great stockRead More...
Smith & Nephew plc (LSE:SN.) delivered an ROE of 16.52% over the past 12 months, which is an impressive feat relative to its industry average of 10.23% during the sameRead More...
One of Massachusetts’ largest medical device employers, London-based Smith & Nephew, has named a new CEO who’ll be familiar to that company’s 1,100 Massachusetts employees.
Artificial hip and knee maker Smith & Nephew (SN.L), a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott (ABT.N) in 2017. The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Medical equipment supplier Smith & Nephew Inc. has selected its Fort Worth facility to locate a $29 million project, creating 100 new jobs. Fort Worth beat out at least three other cities for the project.
LSE:SN), the global medical technology business, today announces the donation of more than $3M of trauma plates and screws, external fixation implants and instruments to The Podiatry Institute (PI). This equipment will be used to support ongoing educational courses conducted at the PI through the American Academy of Foot and Ankle Osteosynthesis (AAFAO). Smith & Nephew has been the sole sponsor of the comprehensive and advanced educational courses conducted by the PI and AAFAO for the past four years, contributing to resident education for nearly 1600 participants.
Measuring Smith & Nephew plc’s (LSE:SN.) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceedRead More...
VANCOUVER , March 7, 2018 /CNW/ - Trading resumes in: Company: Sunniva Inc. CSE Symbol: SNN Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security ...